Navigation Links
iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial

NEWARK, Del., March 21, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced completion of the first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) that began September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of HAC1 produced by iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology. The trial was supported by funding from the Defense Advanced Research Projects Agency (DARPA) and was conducted at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC). Safety and reactogenicity assessments were completed at WRAIR-CTC and immunogenicity evaluation was performed by the Influenza Division of the Centers for Disease Control and Prevention.

The final analyses confirm the results of the June 2, 2011 announcement of the safety and immunogenicity of the HAC1 vaccine which was found to be safe and well tolerated at all dose levels, with or without adjuvant. There were no reported serious adverse events or dose-limiting toxicities. No subjects withdrew from the study as a consequence of an adverse event. The analyses also showed that the HAC1 vaccine elicited high levels of immune responses which correlated directly with the amount of antigen administered when the vaccine was not adjuvanted. The immune response was the highest in subjects who received the non-adjuvanted highest HAC1 dose which was comparable with the immune response of the licensed, control H1N1 vaccine.

A manuscript is under preparation to be published in a peer-reviewed journal. 

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of vaccines and therapeutic proteins using transient gene expression in green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at:

About Fraunhofer USA Center for Molecular Biotechnology
Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist with the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission. Contacts:   


 Robert Erwin, PresidentDouglas Beck, CFOiBio, Inc. 

iBio, Inc.302-355-2335


SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
2. Sunpeaks Ventures Announces Clotamin to be Sold at Navarro Discount Pharmacies
3. OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies
4. HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghais Prestigious Fudan University
5. Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results
6. Sunpeaks Ventures Announces Clotamin available on
7. SurgLine International, Inc. Announces Over 1 Billion Shares Returned to Company
8. Opto-Acoustic Transducers Remove Blockages. ICAP Patent Brokerage Announces for Auction Important Patents for Medical Techniques and Devices That Perform Blockage Removal Using Lasers, Ultrasonics, and Fiber Optics
9. Sihuan Pharmaceutical Announces 2011 Annual Results
10. Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
11. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):